NCT05906537View on ClinicalTrials.gov

SKB410 for Injection in Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

SKB410 for injection

SKB410 for injection is administered every 2 weeks (q2w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY